Research and Clinical Trials

Brief Description  
Roche BP22752 is an open label phase I/II study for HER2-positive, neo-adjuvant, locally advanced breast cancer patients to determine the safety and tolerability of the combination of Trastuzumab-MCC-DM1 (T-DM1) with docetaxel, or TDM-1 with docetaxel and pertuzumab. There will be multiple blood draws (PK's) to evaluate the drug combinations. Standard surgery will be performed at the end of treatment.
Who may be Eligible  

Patients must have newly diagnosed HER2-positive, locally advanced breast cancer defined as stage IIa to stage IIIC disease according to the American Joint Committee on Cancer (AJCC) staging system:

  • T2 to T4d tumor
  • Any N
  • M0
  • Age = 18 years Patient agreement to undergo mastectomy or lumpectomy after neoadjuvant treatment Cannot have cancer that has spread to other parts of your body
IRB Number  
Principal Investigator  
Limentani, Steven

For More Information, Contact  Angela  P, Anderson
Phone:  (704) 355-8243  Fax:  (704) 355-1353  
Address:1100 South Tryon Street Suite 220 Charlotter, NC 28203